MENLO PARK, Calif.,
June 25, 2020 /PRNewswire/ -- Sight
Sciences, Inc., a growth-stage medical device company transforming
the two fastest-growing segments in ophthalmology and optometry,
glaucoma and dry eye disease, today announced two key hires:
Sam Park, joining as Chief Operating
Officer, and Jeremy Hayden, who
joins as General Counsel and Chief Compliance Officer.
"We are excited to be able to add leaders with the outstanding
track records of Sam and Jeremy as Sight Sciences continues to
grow," said Paul Badawi, Chief
Executive Officer of Sight Sciences. "During their careers, both
have proven the ability to scale organizational capabilities and
processes to support the dynamic needs of high-growth medical
device businesses. The ability to add these esteemed professionals
to an already world-class team speaks to our mission-driven company
culture, the substantial opportunity to make an impact on the
fields of glaucoma and dry eye, and the real potential for our
technologies to transform today's standard of care for millions of
patients suffering from these prevalent eye diseases."
Sam Park will be responsible for
scaling the company's manufacturing, operations, and research and
development capabilities to support the company's growth
initiatives. He brings 25 years of medical device experience,
including executive-level leadership roles at SurgRx (acquired by
Johnson & Johnson's Ethicon Endo-Surgery division), Novacept
(acquired by Cytyc), Arthrocare (acquired by Smith+Nephew), Origin
Medsystems (acquired by Eli Lily and
Company), and CardioGenesis (acquired by CryoLife).
Jeremy Hayden has over 20 years
of experience providing legal counsel to life science businesses,
including serving as the in-house counsel for several leading
health care companies. Most recently, Hayden served as General
Counsel and Chief Compliance Officer for Endologix, Inc. (NASDAQ:
ELGX), a medical device company developing devices for aortic
disorders. Prior to this, Hayden served as General Counsel at
publicly traded Cytori Therapeutics, Inc., a biotechnology company
advancing cell therapies, and as a senior legal team member of
Volcano prior to its acquisition by Royal
Philips.
About Sight Sciences
Founded in 2011, Sight Sciences
develops and commercializes intelligently designed and engineered
products that target the underlying causes of the world's most
prevalent eye diseases. The company's surgical glaucoma product
portfolio features the OMNI Surgical System, a dually indicated
MIGS device that facilitates the performance of both ab interno
trabeculotomy and transluminal viscoelastic delivery. Using
proprietary multi-modal functionality, OMNI allows surgeons to
target all three sources of resistance in the conventional outflow
pathway (trabecular meshwork, Schlemm's canal and collector
channels) with a single device and single corneal incision.
The company's non-surgical dry eye product portfolio consists of
the TearCare for ophthalmologists and optometrists. TearCare is a
software-controlled, wearable, therapeutic eyelid technology
designed to melt and clear obstructions of the meibomian glands
within the eyelids. Leveraging the full functionality of the
blinking eye, proprietary SmartLid™ technology is designed to
conform to all eyelid anatomies and achieve therapeutic meibum
melting temperatures at the tarsal conjunctiva thereby clearing
meibomian gland obstructions while sparing the cornea. Improved
meibum production results in a higher quality lipid layer and
higher quality tears.
For more information, please visit sightsciences.com.
TearCare® and OMNI® are registered
trademarks of Sight Sciences.
© 2020 Sight Sciences. All rights reserved.
Media contact:
Shay Smith
Health+Commerce
707.971.9779
shay@healthandcommerce.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/sight-sciences-strengthens-its-leadership-team-with-chief-operating-officer-and-general-counsel-hires-301083381.html
SOURCE Sight Sciences, Inc.